High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
| Autor: | Norbert Grząśko, Agnieszka Druzd-Sitek, Małgorzata Raźny, Anna Waszczuk-Gajda, Aleksandra Wędłowska, Agnieszka Szymczyk, Joanna Drozd-Sokołowska, Anna Dmoszynska, Bartłomiej Pogłódek, Aleksander Perzyński, Grzegorz Charliński, Joanna Mańko, Katarzyna Poniewierska-Jasak, Tadeusz Kubicki, Artur Jurczyszyn, Dominik Dytfeld, Mateusz Sawicki, Dariusz Jawniak, Aleksandra Gałązka, Lidia Usnarska-Zubkiewicz, Monika Długosz-Danecka, Anna Pasternak, Alina Świderska, Anna Kopińska, Iwona Hus, Marek Rodzaj |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
transplant-eligible patients
0301 basic medicine Oncology Cancer Research medicine.medical_specialty 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation first-line therapy Internal medicine medicine Dexamethasone Multiple myeloma business.industry Bortezomib Articles medicine.disease multiple myeloma Thalidomide Transplantation Regimen 030104 developmental biology 030220 oncology & carcinogenesis VTD Stem cell business medicine.drug |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| Popis: | The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly-diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transplantation (HDT/ASCT) in routine clinical practice. With a median of 6 cycles (range, 1–8), at least partial response was achieved in 94.6% and at least very good partial response (VGPR) was achieved in 67.8% of patients. Peripheral neuropathy (PN) grade 2–4 was observed in 28.7% of patients. In 72% of patients undergoing stem cell mobilization one apheresis allowed the number of stem cells sufficient for transplantation to be obtained. Following HDT/ASCT the sCR rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%. The results demonstrated that VTD as an induction regimen was highly efficient in transplant eligible patients with MM with increased at least VGPR rate following prolonged treatment (≥6 cycles). Therapy exhibited no negative impact on stem cell collection, neutrophils and platelets engraftment following ASCT. Therapy was generally well tolerated and PN was the most common reason of dose reduction or treatment discontinuation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|